The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

SITC 2021 | Latest developments in radiopharmaceutical therapies

Name: Latest developments in radiopharmaceutical therapies
Uploaded: 2021-11-12T00:00:00Z
Duration: 1 min 3 s
Description: Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, gives an overview of ongoing work in radiopharmaceutical therapies. Specifically discussed is the pairing of a CD8 antibody fragment with a radioisotope to produce targeted radiotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Ian A. Wilson • 12 Nov 2021

SITC 2021

Gastrointestinal Cancer General Genitourinary Cancer Gynecological Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Antibodies

Ian A. Wilson, PhD, ImaginAb Inc., Los Angeles, CA, gives an overview of ongoing work in radiopharmaceutical therapies. Specifically discussed is the pairing of a CD8 antibody fragment with a radioisotope to produce targeted radiotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.